Verve Therapeutics, Inc. (VERV) Tops Q4 EPS by 14c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.69), $0.14 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $1.17 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22